Abstract
Background/Objective: Prothymosin alpha (proTα) is a ubiquitous polypeptide first isolated by Haritos in 1984, whose role still remains partly elusive. We know that proTα acts both, intracellularly, as an anti-apoptotic and proliferation mediator, and extracellularly, as a biologic response modifier mediating immune responses similarly to molecules termed as “alarmins”. Our research team pioneered the elucidation of the mechanisms underlying the observed activities of proTα.
Results: We were the first to demonstrate that proTα levels increase during normal and abnormal cell proliferation. We showed that proTα acts pleiotropically, inducing immunomodulatory effects on immune cell populations. We revealed that the immunoreactive region of proTα is the carboxyterminal decapeptide proTα(100-109) and both molecules stimulate innate immune responses, signaling through Toll-like receptors (TLRs), specifically TLR-4. We reported that proTα and proTα(100-109) bind on the surface of human neutrophils on sites involving TLR-4, and cell activation is complemented by cytoplasmic calcium ion influx. Further, we showed that proTα and proTα(100-109) act as adjuvants upstream of lymphocyte stimulation and, in the presence of antigen, promote the expansion of antigen-reactive effectors. Most recently, we reported that proTα(100-109) may accumulate in experimentally inflamed sites and can serve as a surrogate biomarker in severe bacterial infections, proposing that extracellular release of proTα or proTα(100- 109) alerts the immune system during conditions of danger. Conclusion: We, therefore, suggest that proTα, and likely proTα(100-109), act as alarmins, being important immune mediators as well as biomarkers, and could eventually become targets for new therapeutic/diagnostic approaches in immune-related diseases like cancer, inflammation, and sepsis.Keywords: Prothymosin alpha, proTα(100-109), alarmin, cancer, inflammation, sepsis.
Current Medicinal Chemistry
Title:Prothymosin Alpha: An Alarmin and More...
Volume: 24 Issue: 17
Author(s): Pinelopi Samara, Chrysoula-Evangelia Karachaliou, Kyriaki Ioannou, Nikos E. Papaioannou, Ioannis F. Voutsas, Christos Zikos, Ioannis Pirmettis, Minas Papadopoulos, Hubert Kalbacher, Evangelia Livaniou, Ourania E. Tsitsilonis* Wolfgang Voelter
Affiliation:
- Section of Animal & Human Physiology, Department of Biology, National and Kapodistrian University of Athens, Panepistimiopolis, Athens 15784,Greece
Keywords: Prothymosin alpha, proTα(100-109), alarmin, cancer, inflammation, sepsis.
Abstract: Background/Objective: Prothymosin alpha (proTα) is a ubiquitous polypeptide first isolated by Haritos in 1984, whose role still remains partly elusive. We know that proTα acts both, intracellularly, as an anti-apoptotic and proliferation mediator, and extracellularly, as a biologic response modifier mediating immune responses similarly to molecules termed as “alarmins”. Our research team pioneered the elucidation of the mechanisms underlying the observed activities of proTα.
Results: We were the first to demonstrate that proTα levels increase during normal and abnormal cell proliferation. We showed that proTα acts pleiotropically, inducing immunomodulatory effects on immune cell populations. We revealed that the immunoreactive region of proTα is the carboxyterminal decapeptide proTα(100-109) and both molecules stimulate innate immune responses, signaling through Toll-like receptors (TLRs), specifically TLR-4. We reported that proTα and proTα(100-109) bind on the surface of human neutrophils on sites involving TLR-4, and cell activation is complemented by cytoplasmic calcium ion influx. Further, we showed that proTα and proTα(100-109) act as adjuvants upstream of lymphocyte stimulation and, in the presence of antigen, promote the expansion of antigen-reactive effectors. Most recently, we reported that proTα(100-109) may accumulate in experimentally inflamed sites and can serve as a surrogate biomarker in severe bacterial infections, proposing that extracellular release of proTα or proTα(100- 109) alerts the immune system during conditions of danger. Conclusion: We, therefore, suggest that proTα, and likely proTα(100-109), act as alarmins, being important immune mediators as well as biomarkers, and could eventually become targets for new therapeutic/diagnostic approaches in immune-related diseases like cancer, inflammation, and sepsis.Export Options
About this article
Cite this article as:
Samara Pinelopi, Karachaliou Chrysoula-Evangelia , Ioannou Kyriaki, E. Papaioannou Nikos , F. Voutsas Ioannis , Zikos Christos, Pirmettis Ioannis , Papadopoulos Minas, Kalbacher Hubert , Livaniou Evangelia, E. Tsitsilonis Ourania*, Voelter Wolfgang, Prothymosin Alpha: An Alarmin and More..., Current Medicinal Chemistry 2017; 24 (17) . https://dx.doi.org/10.2174/0929867324666170518110033
DOI https://dx.doi.org/10.2174/0929867324666170518110033 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Angiotensin Converting Enzyme Inhibitory Peptides Derived from Food Proteins: Biochemistry, Bioactivity and Production
Current Pharmaceutical Design Meet Our Editorial Board
Current Alzheimer Research Transcatheter Aortic Valve Implantation Infective Endocarditis: Current Data and Implications on Prophylaxis and Management
Current Pharmaceutical Design Combined Treatment with PPAR-γ Agonists in Pancreatic Cancer: A Glimmer of Hope for Cancer Therapy?
Current Cancer Drug Targets The Anti-Tumor Activity of Afatinib in Pancreatic Ductal Adenocarcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry In Silico ADME Prediction: Data Sets and Models
Current Computer-Aided Drug Design Novel Metals and Metal Complexes as Platforms for Cancer Therapy
Current Pharmaceutical Design Hemangiomas, Angiosarcomas, and Vascular Malformations Represent the Signaling Abnormalities of Pathogenic Angiogenesis
Current Molecular Medicine Preface
Current Pharmaceutical Design Editorial (Thematic Issue: Treatment of Cancer in the Elderly)
Anti-Cancer Agents in Medicinal Chemistry GIST and Breast Cancer: 3 Case Reports and a Review of the Literature
Current Cancer Therapy Reviews EDITORIAL (Hot Topic: “Signal Transduction and Response to Anti-Cancer Therapy”)
Current Signal Transduction Therapy Parenteral Drug Delivery: A Review
Recent Patents on Drug Delivery & Formulation Transport Mechanism-Based Drug Molecular Design: Novel Camptothecin Analogues to Circumvent ABCG2-associated Drug Resistance of Human Tumor Cells
Current Pharmaceutical Design Beyond Hemostasis: The Role of Platelets in Inflammation, Malignancy and Infection
Cardiovascular & Hematological Disorders-Drug Targets Potential Adverse Effects Associated with Inhibition of p38α/β MAP Kinases
Current Topics in Medicinal Chemistry Anti-Apoptotic Mechanisms of Drug Resistance in Cancer
Current Cancer Drug Targets Can We Predict the Sites of the Recurrence of Ovarian Cancer by F-18 FDG PET/CT Depending on CA-125 Level?
Current Medical Imaging Multiple-Target Drugs: Inhibitors of Heat Shock Protein 90 and of Histone Deacetylase
Current Drug Targets Overview
Anti-Cancer Agents in Medicinal Chemistry